Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Antón A, Martinez-Villacampa M, Marcuello E, Massutí B, Aranda E, Manzano JL, Guallar JL, Diaz-Rubio E. Abad A, et al. Among authors: manzano jl. Clin Colorectal Cancer. 2005 Mar;4(6):384-9. doi: 10.3816/ccc.2005.n.010. Clin Colorectal Cancer. 2005. PMID: 15807931 Clinical Trial.
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Abad A, Massutí B, Gallego J, Yuste AL, Manzano JL, Carrato A, Antón A, Marfa X, Diaz-Rubio E; Spanish Cooperative Group for Gastrointestinal Tumor Therapy. Abad A, et al. Among authors: manzano jl. Anticancer Drugs. 2004 Jun;15(5):469-71. doi: 10.1097/01.cad.0000127146.50172.8a. Anticancer Drugs. 2004. PMID: 15166620 Clinical Trial.
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Abad A, Massuti B, Antón A, Vega ME, Yuste AL, Marcuello E, Manzano JL, Alonso V, Carrato A, Martinez-Villacampa M, Tabernero J, Aranda E, Rivera F, Díaz-Rubio E; Spanish Cooperative Group for Digestive Tumor Therapy. Abad A, et al. Among authors: manzano jl. Acta Oncol. 2008;47(2):286-92. doi: 10.1080/02841860701630259. Acta Oncol. 2008. PMID: 17957505 Clinical Trial.
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, Díaz-Rubio E, Gómez-España A, Aparicio J, García T, Maestu I, Martínez-Cardús A, Ginés A, Guino E; Spanish Group for the Treatment of Digestive Tumours. Martinez-Balibrea E, et al. Among authors: manzano jl. Eur J Cancer. 2008 Jun;44(9):1229-37. doi: 10.1016/j.ejca.2008.03.025. Epub 2008 Apr 28. Eur J Cancer. 2008. PMID: 18448328 Clinical Trial.
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V. Martinez-Balibrea E, et al. Among authors: manzano jl. Br J Cancer. 2010 Aug 10;103(4):581-9. doi: 10.1038/sj.bjc.6605776. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628391 Free PMC article. Clinical Trial.
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Carrato A, et al. Among authors: manzano jl. Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19. Eur J Cancer. 2017. PMID: 28633089 Free article. Clinical Trial.
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.
Carrato A, Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E, González E, Grávalos C, Constenla M, Manzano JL, Losa F, Maurel J, Dueñas R, Massuti B, Gallego J, Aparicio J, Antón A, Aranda E. Carrato A, et al. Among authors: manzano jl. Clin Transl Oncol. 2013 Sep;15(9):705-11. doi: 10.1007/s12094-012-0993-x. Epub 2013 Jan 29. Clin Transl Oncol. 2013. PMID: 23359181 Clinical Trial.
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Martinez-Balibrea E, Manzano JL, Martinez-Cardus A, Moran T, Cirauqui B, Catot S, Taron M, Abad A. Martinez-Balibrea E, et al. Among authors: manzano jl. Oncol Rep. 2007 Mar;17(3):637-45. Oncol Rep. 2007. PMID: 17273745
138 results